Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: GPCR structuretx.com
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic conditions, with a primary focus on obesity. The company leverages a structure-based drug discovery platform targeting G protein-coupled receptors (GPCRs) to create proprietary compounds designed to overcome the scalability limitations of injectable biologic and peptide therapies. Its lead program, aleniglipron, is an oral small molecule GLP-1 receptor agonist currently in Phase 3 clinical trials for chronic weight management. The pipeline also includes ACCG-2671 and ACCG-3535, oral small molecule dual amylin and calcitonin receptor agonists in early clinical development, as well as a planned combination program pairing GLP-1 and amylin receptor agonists. The company is pre-revenue and trades on NASDAQ under the ticker GPCR. Updated
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether…
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic conditions, with a primary focus on obesity.
The Wall Street consensus 12-month price target for GPCR is $105.78.
